Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Adoptively Infused Memory-like Natural Killer Cells Impact Adaptive Immune Responses in Patients with Acute Myeloid Leukemia

Sergio Rutella, Jayakumar Vadakekolathu, Amanda F Cashen, Nitin Mahajan, Yanira Ruiz-Heredia, Alejandro Martín-Muñoz, Santiago Barrio, Melissa M Berrien-Elliott, Jan Davidson-Moncada, Todd A Fehniger

Blood (2023) 142 (Supplement 1): 4813.

https://doi.org/10.1182/blood-2023-184986

Published: 2023

Journal Articles

Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL)

Armin Ghobadi, Ibrahim Aldoss, Shannon L. Maude, Deepa Bhojwani, Alan S. Wayne, Ashish Bajel, Rawan Faramand, Ryan J Mattison, Bhagirathbhai Dholaria, Michael P. Rettig, Ken Jacobs, Ouiam Bakkacha, John Muth, Angela Pannunzio, Brett Ramsey, Eileen McNulty, Matt L. Cooper, Jan Davidson-Moncada, John F. DiPersio

Blood (2023) 142 (Supplement 1): 770.

https://doi.org/10.1182/blood-2023-178723

Published: 2023

Journal Articles

WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Intrinsically Overcomes Factors Restricting Adoptive Cell Therapy (ACT) in Acute Myeloid Leukemia (AML)

Blood (2023) 142 (Supplement 1): 466.

https://doi.org/10.1182/blood-2023-184923

Published: 2023

Journal Articles

WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Naturally Overcomes Tumor Microenvironment (TME) Metabolic Challenges, Retaining Anti-Tumor Potency

Nupur Bhatnagar, Vincent Petit, Jayakumar Vadakekolathu, Christian Pinset, Nitin Mahajan, John Dean, Christine Spingola, Laura Arthur, David Boocock, Clare Coveney, John Muth, Jan Baughman, Melissa M Berrien-Elliott, Marc Sitbon, Matthew L. Cooper, Jan Davidson-Moncada, Todd A Fehniger, Sergio Rutella

Blood (2023) 142 (Supplement 1): 4834.

https://doi.org/10.1182/blood-2023-178868

Published: 2023

Journal Articles

Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies

Michael P Rettig, PhD, John Godwin, MD, Norbert Vey, Bernard Fox, PhD, Carmen Ballesteros-Merino, PhD, Carlo B Bifulco, MD, Daner Li, MS, Daniel Primo, PhD, Joan Ballesteros, PhD, Jichao Sun, PhD, Helene Lelièvre, PhD PharmD, Jan Baughman, MPH, Ross La Motte-Mohs, PhD, John Muth, MS, Paul Moore, PhD, Ezio Bonvini, MD, Jon Wigginton, John F DiPersio, MD PhD, Jan Davidson-Moncada, MDPhD

Blood (2017) 130 (Supplement 1): 1365.

https://doi.org/10.1182/blood.V130.Suppl_1.1365.1365

Published: 2017

Journal Articles

Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Blood (2017) 130 (Supplement 1): 637.

https://doi.org/10.1182/blood.V130.Suppl_1.637.637

Published: 2017

Journal Articles

A Novel Method to Study the in Vivo Trafficking and Homing of Adoptively Transferred NK Cells in Rhesus Macaques and Humans

Jan Davidson-Moncada, MD PhD MSc, Noriko Sato, MD PhD, Robert F Hoyt, DVM, Robert N Reger, Marvin Thomas, DVM, MS, Randy Clevenger, Mark E. Metzger, Robert E. Donahue, Philip C Eclarinal, BS, CNMT, Lawrence Szajek, Gary L Griffiths, PhD, Cynthia E. Dunbar, MD, Peter Choyke, MD, Richard Childs, MD

Blood (2014) 124 (21): 659.

https://doi.org/10.1182/blood.V124.21.659.659

Published: 2014

NARROW

Adoptively Infused Memory-like Natural Killer Cells Impact Adaptive Immune Responses in Patients with Acute Myeloid Leukemia

Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL)

WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Intrinsically Overcomes Factors Restricting Adoptive Cell Therapy (ACT) in Acute Myeloid Leukemia (AML)

WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Naturally Overcomes Tumor Microenvironment (TME) Metabolic Challenges, Retaining Anti-Tumor Potency

Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies

Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

A Novel Method to Study the in Vivo Trafficking and Homing of Adoptively Transferred NK Cells in Rhesus Macaques and Humans

Email alerts

ASH Publications

American Society of Hematology

Adoptively Infused Memory-like Natural Killer Cells Impact Adaptive Immune Responses in Patients with Acute Myeloid Leukemia

Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL)

WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Intrinsically Overcomes Factors Restricting Adoptive Cell Therapy (ACT) in Acute Myeloid Leukemia (AML)

WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Naturally Overcomes Tumor Microenvironment (TME) Metabolic Challenges, Retaining Anti-Tumor Potency

Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies

Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

A Novel Method to Study the in Vivo Trafficking and Homing of Adoptively Transferred NK Cells in Rhesus Macaques and Humans

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only